Commit Biologics appoints accomplished R&D executive, Dr Janine Schuurman, to its Board of Directors
- Former senior vice president of antibody research at Genmab who has co-invented numerous FDA-approved therapeutic antibodies and as well as its DuoBody® bi-specific antibody platform.
- Brings decades of experience in developing strong pipelines of antibody-based drugs from platforms, growing scientific teams and managing partnerships with Pharma companies
- Appointment comes as Commit looks to progress towards drug candidate (DC) nomination in cancer and autoimmune disease in 2025
Aarhus, Denmark, 8 January 2025 – Commit Biologics (“Commit”), a pioneer in the activation of the complement system to treat cancer and autoimmune disease, today announces the appointment of Janine Schuurman, Ph.D. to its Board of Directors.
